Les essais en cours

COLORECTAL

• Prodige 90 :PREDIR-NEOREC Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients: a Randomized Phase II Trial Phase II Randomized Study Non-comparative - Multicenter
  https://clinicaltrials.gov/study/NCT06762405?term=PREDIR-NEOREC&rank=1
  
  
• PREMICES : Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for Patients With Mismatch Repair-deficient or Microsatellite Instability-high (dMMR/MSI-H) Localized Colon Cancer: a Randomized GERCOR G-109 PRODIGE 84 PREMICES Phase II Trial
  https://clinicaltrials.gov/study/NCT06646445?term=premices&rank=1
  
  
• CIRCULATE PRODIGE 70 : CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II
  https://clinicaltrials.gov/study/NCT04120701?term=circulate&rank=3
  
  
• FUDOSE: ihydropyrimidine Dehydrogenase (DPD) Phenotype-guided Dose Individualization of Fluoropyrimidine-based Chemotherapy in DPD Deficient Patients With Gastrointestinal Cancers
  https://clinicaltrials.gov/study/NCT06475352?term=fudose&rank=1
  
  
• (OrigAMI-2) :A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
  https://clinicaltrials.gov/study/NCT06662786?term=OrigAMI-2&rank=1 Colorectal Cancer
  
  
• An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer
  https://clinicaltrials.gov/study/NCT05253651?term=MOUNTAINEER-03&rank=1
  
  
• ONO-4578-10 : A Randomized, Open Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo® in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care for First-line Treatment of Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
  https://clinicaltrials.gov/study/NCT06948448?term=ONO-4578-10&rank=1
  
  
• TRIFLUOX-DP: Safety of Trifluridine/Tipiracil as Replacement of Fluoropyrimidines (5-fluorouracil and Capecitabine) Based Chemotherapy as First Line Metastatic Colorectal or Gastroesophageal Cancer Regimens in Patients With Dihydropyrimidine Dehydrogenase Deficiency: a Phase II Trial
  https://clinicaltrials.gov/study/NCT06245356?term=TRIFLUOX-DP&rank=1
  
  
• REPROGRAM-02 : Induction Regorafenib in Combination With Metronomic Cyclophosphamide, Capecitabine, and Low-dose Aspirin Followed by Chemotherapy in Second Line Metastatic Colorectal Cancer Carcinoma An Open-label Randomized Phase II-III Study
  https://clinicaltrials.gov/study/NCT05462613?term=REPROGRAM-02&rank=1
  
  
• TARGETMONITO : Dosing of Various Multi Kinases Inhibitors Plasma Concentrations for Patients Treated for Their Advanced Digestive Cancer, With the Aim to Determine the Best Optimal Dose for Each Treatment, in the Future
  https://clinicaltrials.gov/study/NCT05443087?term=TARGETed%20therapy%20drug%20MONITOring%20in%20DIGestive%20oncology&rank=1
  
  
• Rosetta BMS CA266-0003: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
  https://clinicaltrials.gov/study/NCT07221357?term=BMS%20CA266-0003&viewType=Card&rank=1
  
  
• KANDLELIT-012 (G12C): MK1084-012 A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 with or without Bevacizumab as First-line Treatment of Participants with KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer
  https://clinicaltrials.gov/study/NCT06997497?term=NCT06997497%20&viewType=Card&rank=1
  
  
• BETWEEN G-124 : Biweekly Bevacizumab + Trifluridine/​Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients .
  https://clinicaltrials.gov/study/NCT07071844?term=NCT07071844&viewType=Card&rank=1
  
  
• ARTIOS : A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors
  https://clinicaltrials.gov/study/NCT04657068?term=NCT04657068&viewType=Card&rank=1
  
  
• ORGANOTREAT : Prospective Multicenter Study Evaluating Feasibility and Efficacy of Tumor Organoid-based Precision Medicine in Patients With Advanced Refractory Cancers
  https://clinicaltrials.gov/study/NCT05267912?term=NCT05267912&viewType=Card&rank=1
  
  
• AMG 436 as Monotherapy and Combination Therapy in Partcipants With MSI-H/dMMR solid Tumors
  https://clinicaltrials.gov/study/NCT07403721?term=NCT07403721&viewType=Card&rank=1
  

PANCREAS

• Pan-MSI-ACSE : Dostarlimab as First-line Treatment for Patients With dMMR/MSI (Non-colorectal/Non-endometrial) Locally Advanced or Metastatic Cancer: a Randomized Phase 2 Trial (Cohort Pan-MSI ACSE) With Crossover in the Standard Arm at Progression
  https://clinicaltrials.gov/study/NCT06333314?term=Pan-MSI&rank=2
  
  
• EMBOLD PanTumor-101 : A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 as Monotherapy and in Combination in Participants With Advanced Solid Tumors https://clinicaltrials.gov/study/NCT06551142?term=GSK%20EMBOLD%20&rank=2
  
  
• PRODIGE 104 B NEOPREDICT : Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)
  https://clinicaltrials.gov/study/NCT07592819?term=NCT07592819&viewType=Card&rank=1
  
  
• PRODIGE-98 AMPIRINOX : Randomized, Multicenter Phase 3 Trial of Adjuvant Chemotherapy With Modified FOLFIRINOX Versus Capecitabine or Gemcitabine in Patients With Resected Ampullary Adenocarcinoma
  https://clinicaltrials.gov/study/NCT06813976?term=NCT06813976&viewType=Card&rank=1
  
  
• PANORAMIX : Optimisation du traitement de première ligne du cancer du pancréas par NALIRIFOX avec maintenance par 5-FU et rôle des antibiotiques et de l'exploration du microbiote dans le traitement de deuxième ligne - Étude de phase II non comparative et randomisée
  https://clinicaltrials.gov/study/NCT07028424?term=NCT07028424&viewType=Card&rank=1
  
  
• ARTIOS : A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors
  https://clinicaltrials.gov/study/NCT04657068?term=NCT04657068&viewType=Card&rank=1
  
  
• ORGANOTREAT Prospective Multicenter Study Evaluating Feasibility and Efficacy of Tumor Organoid-based Precision Medicine in Patients With Advanced Refractory Cancers
  https://clinicaltrials.gov/study/NCT05267912?term=NCT05267912&viewType=Card&rank=1
  

GASTRIQUE

• BIG : Gut Microbiome Intervention With EXL01 in Combination With Nivolumab and FOLFOX as First-line Treatment for Patients With PD-L1 CPS ≥5 Metastatic Gastric Cancer: A Randomized GERCOR Phase II
  https://clinicaltrials.gov/study/NCT06253611?term=BIG%20gercor&rank=1
  
  
• Destiny-Gastric05 : A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer
  https://clinicaltrials.gov/study/NCT06731478?term=DESTINY-gastric05&rank=1
  
  
• Pan-MSI-ACSE : Dostarlimab as First-line Treatment for Patients With dMMR/MSI (Non-colorectal/Non-endometrial) Locally Advanced or Metastatic Cancer: a Randomized Phase 2 Trial (Cohort Pan-MSI ACSE) With Crossover in the Standard Arm at Progression
  https://clinicaltrials.gov/study/NCT06333314?term=Pan-MSI&rank=2
  
  
• TRIFLUOX-DP: Safety of Trifluridine/Tipiracil as Replacement of Fluoropyrimidines (5-fluorouracil and Capecitabine) Based Chemotherapy as First Line Metastatic Colorectal or Gastroesophageal Cancer Regimens in Patients With Dihydropyrimidine Dehydrogenase Deficiency: a Phase II Trial
  https://clinicaltrials.gov/study/NCT06245356?term=TRIFLUOX-DP&rank=1
  
  
• IDeate-Esophageal01 : A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
  https://clinicaltrials.gov/study/NCT06644781?term=IDeate-Esophageal01&rank=1
  
  
• DEWI G-12 : Watch-and-Wait With Dostarlimab in Localized dMMR/​MSI-H Gastric/​GEJ Adenocarcinoma Phase II Study
  https://clinicaltrials.gov/study/NCT06059495?term=NCT06059495&rank=1
  
  
• AMG 436 as Monotherapy and Combination Therapy in Partcipants With MSI-H/dMMR solid Tumors
  https://clinicaltrials.gov/study/NCT07403721?term=NCT07403721&viewType=Card&rank=1

VOIES BILIAIRES

• SAFIR-ABC10 : Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial
  https://clinicaltrials.gov/study/NCT05615818?term=PRODIGE%2078&rank=1
  
  
• AMG 436 as Monotherapy and Combination Therapy in Partcipants With MSI-H/dMMR solid Tumors
  https://clinicaltrials.gov/study/NCT07403721?term=NCT07403721&viewType=Card&rank=1
  

GIST ET NEURO-ENDOCRINE

• NEONEC : Phase II Study to Evaluate the Efficacy of 12-month Neoadjuvant Chemotherapy in Terms of Disease-free Survival in Patients With Localized Digestive Neuroendocrine Carcinomas
  https://clinicaltrials.gov/study/NCT04268121?term=neonec&rank=1
  
  
• FOLFIRINEC : Folfirinox Versus Platinum - Etoposide as First Line Chemotherapy for Metastatic Grade 3 Poorly Differentiated Neuroendocrine Carcinoma of Gastro Entero Pancreatic and Unknown Primary Associated With Molecular Profiling for Therapeutic Targets & Predictive Biomarkers Identification
  https://clinicaltrials.gov/study/NCT04325425?term=FOLFIRINEC%20&rank=1
  
  
• Pan-MSI-ACSE : Dostarlimab as First-line Treatment for Patients With dMMR/MSI (Non-colorectal/Non-endometrial) Locally Advanced or Metastatic Cancer: a Randomized Phase 2 Trial (Cohort Pan-MSI ACSE) With Crossover in the Standard Arm at Progression
  https://clinicaltrials.gov/study/NCT06333314?term=Pan-MSI&rank=2
  
  
• TARGETMONITO : Dosing of Various Multi Kinases Inhibitors Plasma Concentrations for Patients Treated for Their Advanced Digestive Cancer, With the Aim to Determine the Best Optimal Dose for Each Treatment, in the Future
  https://clinicaltrials.gov/study/NCT05443087?term=TARGETed%20therapy%20drug%20MONITOring%20in%20DIGestive%20oncology&rank=1
  
  
• GCO-003 TARLANEC : Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas
  https://clinicaltrials.gov/study/NCT06937905?term=NCT06937905&viewType=Card&rank=1